Vascular endothelial growth factor gene 460 polymorphism is associated with pterygium formation in female patients

other OA: closed public-domain-us
Full text JSON View on PubMed View at publisher
AI-generated summary by gemini-2.5-flash-lite, 2026-06-07

The VEGF-460C polymorphism is associated with pterygium formation in females, with carriers of the C allele having an increased risk of developing pterygium at a younger age.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by qwen3.7-flash, 2026-09-10 · read from full text

This study investigated the association between VEGF-460 polymorphism and pterygium formation in a cohort of 127 patients and 102 controls. While no significant difference was found in the overall population, stratification by sex revealed that female carriers of at least one C allele had a significantly increased risk of developing pterygium compared to those with the T/T genotype. The researchers noted that this genetic susceptibility appeared to manifest at a younger age in women, whereas no such association was observed in male patients. Relevance to endometriosis: listed as one indication for GnRH antagonists, though the paper's main focus is uterine fibroids.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

PURPOSE: Pterygium is composed of proliferating fibrovascular tissue, and its formation and progression require neovascularization. Vascular endothelial growth factor (VEGF) is a specific mitogen for vascular endothelial cells and is essential for neovascularization. Recently, the VEGF-460 polymorphism was reported to be associated with increased VEGF basal promoter activity and with several fibrovascular diseases, such as proliferative diabetic retinopathy, endometriosis, and chronic renal disease. Therefore, this study evaluated the potential association between pterygium formation and VEGF-460 polymorphism. METHODS: One hundred twenty-seven pterygium patients and 102 volunteers without pterygium were enrolled in this study. Polymerase chain reaction-restriction fragment length polymorphism analysis was used to resolve the VEGF-460 genotypes of pterygium patients and normal controls. RESULTS: There were no significant differences between pterygium and control groups in age, sex, and distribution of genotype and allelic frequency of VEGF-460 polymorphism. However, when results were stratified by sex, there were significant differences between female patients and controls in the distribution of genotype and allelic frequency of VEGF-460 polymorphism. Females who carried at least 1 C allele (C/C and C/T genotypes) had about a 2.5-fold increased risk of developing pterygium compared with those who carried the T/T genotype, and there was a significantly higher frequency of C/C and C/T genotypes in younger female patients than in older female patients. There were no differences between male patients and controls in the distribution of genotype and allelic frequency of the VEGF-460 polymorphism. CONCLUSIONS: VEGF-460C polymorphism is associated with pterygium formation in female patients. Females who carried the C allele have increased risk of developing pterygium at a younger age.
Full text 2,128 characters · extracted from oa-doi-fallback · 3 sections · click to expand

Methods

One hundred twenty-seven pterygium patients and 102 volunteers without pterygium were enrolled in this study. Polymerase chain reaction-restriction fragment length polymorphism analysis was used to resolve the VEGF-460 genotypes of pterygium patients and normal controls.

Results

There were no significant differences between pterygium and control groups in age, sex, and distribution of genotype and allelic frequency of VEGF-460 polymorphism. However, when results were stratified by sex, there were significant differences between female patients and controls in the distribution of genotype and allelic frequency of VEGF-460 polymorphism. Females who carried at least 1 C allele (C/C and C/T genotypes) had about a 2.5-fold increased risk of developing pterygium compared with those who carried the T/T genotype, and there was a significantly higher frequency of C/C and C/T genotypes in younger female patients than in older female patients. There were no differences between male patients and controls in the distribution of genotype and allelic frequency of the VEGF-460 polymorphism.

Conclusions

VEGF-460C polymorphism is associated with pterygium formation in female patients. Females who carried the C allele have increased risk of developing pterygium at a younger age.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Polymorphism, Single Nucleotide Pterygium Vascular Endothelial Growth Factor A Adult Aged Aged, 80 and over Case-Control Studies Female Gene Frequency Genotype Humans Male Middle Aged Polymerase Chain Reaction Polymorphism, Restriction Fragment Length Pterygium Risk Factors Sex Factors Vascular Endothelial Growth Factor A

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-09-19T06:15:14.566301+00:00
pubmed
last seen: 2026-05-13T22:14:36.758325+00:00
unpaywall
last seen: 2026-09-19T06:31:22.526400+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine